uniQure 2025 Q2 Earnings Narrows Losses by 33%

uniQure (QURE) reported its fiscal 2025 Q2 earnings on Jul 29th, 2025. uniQure's Q2 2025 earnings results showed a significant narrowing of losses compared to the previous year, although revenue fell short of prior levels. The company's continued investment in promising therapeutic developments, such as AMT-130, aligns with its strategic objectives. The projected cash runway into 2027 supports ongoing initiatives. The market's reaction to these results will likely focus on the progression of key clinical programs and future revenue potential. Guidance remains optimistic, with a focus on the anticipated launch of AMT-130 in 2026.

Revenue
uniQure's total revenue declined by 52.7% to $5.26 million in Q2 2025, compared to $11.13 million in Q2 2024. The entirety of this revenue came from license agreements, underscoring the company's strategic focus on licensing income as a primary revenue stream.

Earnings/Net Income
uniQure narrowed its losses to $0.69 per share in Q2 2025, a significant improvement from the $1.16 loss per share recorded in Q2 2024. The net loss also decreased to $37.72 million, showing a 33.0% reduction from the previous year's $56.30 million net loss. This improvement indicates a positive trend in operational efficiency despite ongoing challenges.

Price Action
The stock price of uniQure has dropped 7.19% during the latest trading day, has dropped 4.00% during the most recent full trading week, and has dropped 3.87% month-to-date.

Post-Earnings Price Action Review
The investment strategy of purchasing uniQure (QURE) shares after a quarter-over-quarter revenue increase and holding for 30 days resulted in moderate returns but underperformed compared to the broader market. The strategy achieved a compound annual growth rate (CAGR) of 10.03%, falling short of the benchmark by 26.50%. Despite a maximum drawdown of 0.00% and a Sharpe ratio of 0.21, which indicates low risk and modest returns, the strategy's overall effectiveness was limited in comparison to broader market indicators. Investors may seek other strategies or consider uniQure's broader market position before committing to this approach.

CEO Commentary
Matthew Kapusta, CEO & Executive Director, stated that the first half of 2025 has been "tremendously productive" for uniQure as they advance AMT-130 towards becoming the first disease-modifying therapy for Huntington's disease. He emphasized strong momentum across clinical advancement, regulatory alignment, BLA readiness, and commercial launch preparation. Kapusta highlighted the achievement of breakthrough therapy designation for AMT-130 and alignment with the FDA on statistical analysis and CMC requirements for a planned BLA submission in early 2026. He expressed pride in the team's execution and dedication, ensuring that the second half of 2025 is shaping up to be "eventful" with meaningful data updates and regulatory progress.

Guidance
uniQure expects to present pivotal top-line data in September 2025, which will support a planned BLA submission in the first quarter of 2026. The company anticipates that cash, cash equivalents, and investment securities will be sufficient to fund operations into the second half of 2027. In Q2 2025, uniQure reported revenue of $5.3 million with an EPS of -0.69. The leadership remains optimistic about the potential commercial launch of AMT-130 in 2026, focusing on disciplined investments in preparation for this launch.

Additional News
In June 2025, uniQure appointed Kylie O'Keefe as Chief Customer and Strategy Officer, enhancing the leadership team with her extensive commercial experience. O'Keefe previously served as Chief Commercial Officer at PTC Therapeutics, bringing valuable expertise in global commercial strategy and operations. Additionally, uniQure highlighted significant progress in its clinical programs, including AMT-260, which showed a 92% reduction in seizures in a patient with refractory mesial temporal lobe epilepsy, and ongoing developments in the Fabry disease and ALS programs. These advancements underscore uniQure's commitment to expanding its pipeline of proprietary gene therapies for severe medical conditions.